Vogenx Inc (NASDAQ:VOGX – Get Free Report) was the recipient of a large growth in short interest in August. As of August 14th, there was short interest totaling 25,591 shares, a growth of ∞ from the July 30th total of 0 shares. Approximately 0.2% of the company’s shares are short sold. Based on an average daily volume of 69,269 shares, the short-interest ratio is presently 0.4 days.
Vogenx Trading Up 1.0%
Vogenx stock opened at $33.96 on Friday. Vogenx has a 12-month low of $12.95 and a 12-month high of $35.50.
Analyst Upgrades and Downgrades
Separately, Wall Street Zen upgraded shares of Vogenx to a “hold” rating in a research note on Saturday, August 22nd.
Vogenx Company Profile
Vogenx Inc is a clinical-stage biopharmaceutical company. It focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including PBH and gastroparesis. The company’s product candidate includes mizagliflozin, is an orally administered, minimally absorbed small molecule drug candidate in development for the treatment of PBH, gastroparesis, and GIP-dependent Cushing’s Syndrome. Vogenx Inc is based in RALEIGH, NC.
See Also
- Five stocks we like better than Vogenx
- Amazon’s Zoox Push Tests Tesla’s Robotaxi Premium as Waymo Widens Its Lead
- MarketBeat Week in Review – 08/24 – 08/28
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
Receive News & Ratings for Vogenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vogenx and related companies with MarketBeat.com's FREE daily email newsletter.
